C-Rad Past Earnings Performance

Past criteria checks 5/6

C-Rad has been growing earnings at an average annual rate of 34.4%, while the Medical Equipment industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 18.6% per year. C-Rad's return on equity is 17.7%, and it has net margins of 10.8%.

Key information

34.4%

Earnings growth rate

32.9%

EPS growth rate

Medical Equipment Industry Growth	6.2%
Revenue growth rate	18.6%
Return on equity	17.7%
Net Margin	10.8%
Next Earnings Update	23 Oct 2024

Recent past performance updates

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Feb 15

Recent updates

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Jun 02

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Jan 30

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

Jul 03

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

Mar 05

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 07

What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?

Jan 17

Is C-Rad's (STO:CRAD B) 179% Share Price Increase Well Justified?

Dec 13

Revenue & Expenses Breakdown

How C-Rad makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OM:CRAD B Revenue, expenses and earnings (SEK Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 24	497	54	257
31 Mar 24	458	48	242
31 Dec 23	425	36	229
30 Sep 23	385	24	216
30 Jun 23	357	20	205
31 Mar 23	329	12	195
31 Dec 22	301	7	179
30 Sep 22	280	14	154
30 Jun 22	260	12	143
31 Mar 22	257	21	131
31 Dec 21	261	25	124
30 Sep 21	258	26	120
30 Jun 21	247	25	114
31 Mar 21	230	17	110
31 Dec 20	222	14	109
30 Sep 20	198	-11	110
30 Jun 20	201	-16	115
31 Mar 20	210	-14	120
31 Dec 19	205	-14	117
30 Sep 19	212	23	114
30 Jun 19	203	24	111
31 Mar 19	204	27	106
31 Dec 18	190	21	105
30 Sep 18	174	-2	101
30 Jun 18	161	-4	94
31 Mar 18	141	-10	91
31 Dec 17	133	-11	88
30 Sep 17	118	-16	84
30 Jun 17	108	-23	83
31 Mar 17	90	-28	80
31 Dec 16	83	-31	75
30 Sep 16	74	-33	71
30 Jun 16	70	-32	67
31 Mar 16	73	-27	62
31 Dec 15	73	-21	58
30 Sep 15	73	-20	57
30 Jun 15	66	-16	52
31 Mar 15	62	-8	50
31 Dec 14	57	-7	47
30 Sep 14	56	-5	45
30 Jun 14	59	-4	44
31 Mar 14	52	-17	44
31 Dec 13	49	-21	44
30 Sep 13	43	-20	39

Quality Earnings: CRAD B has high quality earnings.

Growing Profit Margin: CRAD B's current net profit margins (10.8%) are higher than last year (5.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CRAD B's earnings have grown significantly by 34.4% per year over the past 5 years.

Accelerating Growth: CRAD B's earnings growth over the past year (164%) exceeds its 5-year average (34.4% per year).

Earnings vs Industry: CRAD B earnings growth over the past year (164%) exceeded the Medical Equipment industry 44.1%.

C-Rad Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Recent updates

CEO & President recently bought kr85k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Market Participants Recognise C-Rad AB (publ)'s (STO:CRAD B) Earnings Pushing Shares 29% Higher

Investor sentiment improves as stock rises 16%

C-Rad AB (publ) Appoints Mats Thorén as Board Member

Full year 2023 earnings: EPS and revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Apr 23, 2024

Returns On Capital Are A Standout For C-Rad (STO:CRAD B)

C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?

Price target increased by 12% to kr58.00

C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear

C-Rad AB (publ) to Report Q3, 2024 Results on Oct 23, 2024

Consensus EPS estimates fall by 11%, revenue upgraded

Price target increased by 13% to kr65.50

Third quarter 2023 earnings: Revenues exceed analyst expectations

Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?

Investor sentiment improves as stock rises 19%

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

C-Rad AB (Publ) Announces Former Employee Appeals Verdict from the Patent and Market Court of Appeal

Consensus EPS estimates fall by 14%

New major risk - Earnings quality

C-Rad AB (publ) to Demonstrate Enhancements in Surface Guided Solutions for Advanced Radiotherapy Treatments at AAPM

Second quarter 2023 earnings: Revenues exceed analyst expectations

Less than half of directors are independent

Price target decreased by 11% to kr57.75

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

C-Rad AB (publ) to Report Fiscal Year 2022 Final Results on Apr 06, 2023

C-Rad AB (Publ) Appoints Christoffer Herou as CFO

C-Rad AB (Publ) Announces CEO Changes

Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?

Price target decreased to kr62.50

C-Rad AB (publ) Announces CFO Changes

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analyst expectations

C-Rad AB (publ) to Report Fiscal Year 2023 Results on Feb 02, 2024

Price target decreased to kr62.50

C-RAD Launches New Updated eDucation Portal as an Online Platform

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analyst expectations

Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?

Henrik Bergentoft Resigns as CFO of C-RAD

C-Rad Announces CEO Changes

Chief Financial Officer recently bought kr93k worth of stock

Consensus EPS estimates fall by 41%

Price target decreased to kr72.50

First quarter 2022 earnings: Revenues miss analyst expectations

Returns Are Gaining Momentum At C-Rad (STO:CRAD B)

Insufficient new directors

Insufficient new directors

Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts

Full year 2021 earnings: EPS and revenues miss analyst expectations

C-Rad AB (publ) to Report Q3, 2022 Results on Oct 28, 2022

Price target increased to kr82.00

C-Rad Achieves Another Milestone Ensuring the Availability of SGRT, the Standard of Care for Radiotherapy

Third quarter 2021 earnings released

Chief Operating Officer recently sold kr625k worth of stock

Second quarter 2021 earnings released

C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue

C-Rad AB (publ) Announces The Patent and Market Court Rejected Former Employee Claim for Compensation

The Patent and Market Court of Appeal Issues Judgement Confirming C-Rad's Entitlement to Beamocular's Invention

Full year 2020 earnings released: EPS kr0.43 (vs kr0.45 loss in FY 2019)

Will the Promising Trends At C-Rad (STO:CRAD B) Continue?

C-RAD and Alliance Radiation Oncology Announce That Alliance Has Become the First Center in the Greater Northshore Area to Integrate C-Rad

New 90-day high: kr60.30

President of China exercised options to buy kr1.5m worth of stock.

Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?